At a Case Management Conference in the Multi District Litigation against Pfizer Inc. (NYSE:PFE), the Honorable M. Casey Rodgers set a date for the first Trial, which will take place in December 2026, ...
The FDA approved a new safety warning for Depo-Provera alerting patients to a possible risk for a type of brain tumor called ...
If you’ve experienced serious side effects after using Depo-Provera, you are not alone. The birth control injection has been linked to a range of adverse health effects, including bone density loss, ...
Recent scientific research has uncovered a significant association between the long-term use of Depo-Provera, a widely used injectable contraceptive, and the development of meningiomas, tumors ...
The costs of an intracranial meningioma diagnosis can be substantial. Not only can this diagnosis lead to a lifetime of medical bills and other costs, but it can drastically reduce patients’ quality ...
The MarketWatch News Department was not involved in the creation of this content. The number of lawsuits filed has tripled to over 1300 since May New US peer-reviewed study adds to body of research ...
U.S. District Judge M. Casey Rodgers of the Northern District of Florida is overseeing more than 400 lawsuits alleging that Depo-Provera, an injectable birth control, has caused non-malignant brain ...
Hosted on MSN
Depo Provera brain tumor warning: Why the FDA changed the label and what it means for users
The FDA has approved a critical label change for Pfizer's widely used Depo-Provera birth control injection, adding a warning about the risk of meningioma—a typically non-cancerous but potentially ...
The motion cites 22 cases, most in California, filed against brand manufacturer Pfizer Inc. and authorized generic providers. The motion says most of the plaintiffs will be in Massachusetts or ...
According to the Centers for Disease Control and Prevention (CDC), as of 2017, 65.3% of women between the ages of 15 and 49 in the United States use a form of birth control. Of this population, 10.4% ...
A popular injectable birth control, Depo-Provera (medroxyprogesterone acetate) — also sold as Depo-SubQ Provera 104 — has long been favored for its 99% effectiveness and ease of use compared to daily ...
The decision comes as Pfizer faces lawsuits from more than 1000 women who say the company knew about the risks and didn’t warn them. The agency signed off last week on a label update for 2 versions of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback